KALY - Kali-Extracts Cannabis Biopharma Initiative Stands to Benefit From Upcoming Session of UN Commission on Narcotic Drugs
January 30 2020 - 1:11PM
InvestorsHub NewsWire
KALY - Kali-Extracts Cannabis
Biopharma Initiative Stands to Benefit From Upcoming Session of UN
Commission on Narcotic Drugs
DALLAS, TX -- January 30, 2020 -- InvestorsHub NewsWire --
Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:
KALY) ("KALY") management today commented on the potential
benefit the company could enjoy from the upcoming session in March of the
United Nations Commission on Narcotic Drugs. The session
will include a vote on removing cannabis and cannabis resin from
Schedule IV of the Single Convention on Narcotic Drugs
(1961). The result would be the recognition of cannabis and
cannabis resin having medical value. KALY management
indicated this would have a very positive impact on the company's
ongoing research and development surrounding its U.S. Patented
Cannabis Extraction Process and associated pharmaceutical
formulations.
KALY's cannabis biopharmaceutical technology intellectual
property portfolio contains a deep pipeline of cannabinoid product
candidates including four distinct compounds listed here:
- Chronic Obstructive Pulmonary Disease (COPD) - The market for
COPD treatment is anticipated to reach $14 billion by
2025;
- Type 2 Diabetes - The market for Type 2 Diabetes is expected to
be a $64 billion market by 2026;
- Cancer Pain Management - The overall pain management treatment
market is anticipated to reach $83 billion by 2024,
and
- Epilepsy - The market for epilepsy treatment is anticipated to
reach $9 billion by 2022.
In conjunction with the research already conducted and the next
phase of research now moving forward, KALY recently filed for a new
patent application specifically on its formulation for symptoms
associated with COPD and other similar respiratory
conditions. KALY also filed for a trademark on the name
RespRx as the brand name for its CBD formulation to treat the
symptoms associated with COPD and other similar respiratory
conditions. The market for COPD treatment is anticipated to
reach $14 billion by 2025.
In addition to KALY's ongoing efforts to develop prescription
therapies, KALY has initiated a program to certify its proprietary
CBD extracts derived from KALY's U.S. Patented Extraction Process
as an Over-The-Counter (OTC) drug under the requirements prescribed
by the U.S. Food and Drug Administration.
Follow further developments at https://www.kali-extracts.com/
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), and as such, may involve risks and
uncertainties. These forward looking statements relate to, amongst
other things, current expectation of the business environment in
which the company operates, potential future performance,
projections of future performance and the perceived opportunities
in the market. The company's actual performance, results and
achievements may differ materially from the expressed or implied in
such forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024